{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"1.20","upperLimit":"2.39","value":"1.69"}]}],"title":"Midazolam (CYP3A4 substrate), Cmax"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"1.14","upperLimit":"2.52","value":"1.70"}]}],"title":"Midazolam (CYP3A4 substrate), AUC0-t"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"1.16","upperLimit":"2.53","value":"1.71"}]}],"title":"Midazolam (CYP3A4 substrate), AUC0-inf"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"1.51","upperLimit":"2.75","value":"2.03"}]}],"title":"Fexofenadine (P-gp substrate), Cmax"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"1.65","upperLimit":"2.73","value":"2.12"}]}],"title":"Fexofenadine (P-gp substrate), AUC0-t"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"1.64","upperLimit":"2.78","value":"2.14"}]}],"title":"Fexofenadine (P-gp substrate), AUC0-inf"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"1.59","upperLimit":"3.14","value":"2.23"}]}],"title":"Rosuvastatin (BCRP substrate), Cmax"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"1.31","upperLimit":"3.48","value":"2.13"}]}],"title":"Rosuvastatin (BCRP substrate), AUC0-t"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"1.23","upperLimit":"4.01","value":"2.23"}]}],"title":"Rosuvastatin (BCRP substrate), AUC0-inf"}],"denoms":[{"counts":[{"groupId":"OG000","value":"6"}],"units":"Participants"}],"description":"Participants were administered midazolam, fexofenadine and rosuvastatin (as part of the drug cocktail) as a single dose on Day -2 (without surufatinib) and on Cycle 1 Day 15 (with surufatinib). Separate blood samples were collected for measurement of plasma concentrations of each probe substrate and surufatinib. Probe substrate of midazolam was CYP3A4, fexofenadine was P-gp and rosuvastatin was BCRP. Ratio of LS Mean for maximum plasma concentration (Cmax), area under the plasma concentration-time curve from time 0 to time of last measurable concentration (AUC0-t) and area under the plasma concentration-time curve from time 0 to infinity (AUC0-inf) are presented as Cycle 1 Day 15/Day -2.","dispersionType":"90% Confidence Interval","groups":[{"description":"Patients with NET of any origin received a single dose of drug cocktail (midazolam 2.5 mg, fexofenadine 30 mg and rosuvastatin 10 mg) on Day -2 followed by surufatinib 300 mg orally QD from C1D1 to C1D14. On C1D15, a single dose of surufatinib 300 mg and a single dose of drug cocktail as above was administered. Patients received surufatinib 300 mg orally QD from C1D16 until disease progression, death, unacceptable toxicity, withdrawal of consent or lost to follow-up.","id":"OG000","title":"Cohort D (NET, Any)"}],"paramType":"NUMBER","populationDescription":"The PK evaluable population included all patients who received at least 1 dose of the study drug and had sufficient concentration data to derive at least 1 PK parameter.","reportingStatus":"POSTED","timeFrame":"Baseline (Day -2) and Cycle 1 Day 15","title":"Cohort D: Geometric Least Squares (LS) Mean Ratio of Cytochrome P450 (CYP3A4), P-glycoprotein (P-gp) and Breast Cancer Resistance Protein (BCRP) Substrates at Cycle 1 Day 15 to Baseline","type":"SECONDARY","unitOfMeasure":"Ratio of geometric LS mean"}